Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 4, 2016, to report its financial and operating results for the second quarter ended June 30, 2016. The press release, furnished as Exhibit 99.1, contains the detailed results for the quarter. While the 8-K itself does not provide the specific financial figures, it directs investors to the accompanying press release for comprehensive information on revenue, earnings, and operational performance. Investors should refer to the press release dated August 4, 2016, for key metrics such as revenue growth, net income, earnings per share, and updates on product sales and pipeline developments. This filing serves as an official notification of the release of these results, which are crucial for assessing the company's recent performance and future outlook.
Key Highlights
- 1Regeneron announced its Q2 2016 financial and operating results via press release.
- 2The press release is furnished as Exhibit 99.1 to the 8-K filing.
- 3The filing date is August 4, 2016, with the event date also being August 3, 2016.
- 4Investors are directed to the press release for detailed financial and operational performance data.
- 5This 8-K primarily serves as a notification of the earnings release.
- 6Information furnished under Item 2.02 is not considered 'filed' for certain legal purposes unless expressly incorporated by reference.